top of page

Immunotherapy for Breast Cancer

Sep 28
5 min read

Updated: Nov 11

Medically reviewed by Dr. Baraa Alnahhal, MD · Last reviewed: October 2026

Quick Answer: What Is Immunotherapy for Breast Cancer?

Immunotherapy for breast cancer is a treatment that boosts the body's natural defenses to attack cancer cells. It is currently used for high-risk and metastatic triple-negative breast cancer. [1] Given by IV every three to six weeks, it can significantly improve cure rates and long-term survival for eligible patients, with monitoring for side effects such as fatigue or thyroid issues.

What the research says

  • Immunotherapy before surgery clears more early triple-negative cancers. In 1,174 patients with stage II–III triple-negative breast cancer, adding pembrolizumab to chemotherapy before surgery raised the share with no remaining invasive cancer from 51.2% to 64.8% (first 602 patients analyzed) and lowered the risk of recurrence or progression (hazard ratio 0.63) (Schmid et al., NEJM, 2020) [2].

  • It also extends survival in advanced disease. In 847 patients with advanced triple-negative breast cancer, adding pembrolizumab to chemotherapy raised median overall survival from 16.1 to 23.0 months in those whose tumors had high PD-L1 levels (CPS 10 or more) (Cortes et al., NEJM, 2022) [3].

What Are the Types of Immunotherapy?

Immunotherapy works by either training the immune system to recognize cancer cells more effectively or by providing the body with lab-made tools to enhance its natural response. It is classified into two primary categories based on how it interacts with the immune system.

  • Active immunotherapy: focuses the immune system on specific antigens found on cancer cells. The goal is to train the body to proactively find and kill cancer cells.

  • Passive immunotherapy: uses lab-made drugs to improve existing immune system tools. The goal is to enhance the body's current cancer-fighting capabilities.

Which Immunotherapy Medications Are Approved for Breast Cancer?

The regulatory landscape for breast cancer immunotherapy is evolving, with specific drugs approved for particular stages and types of the disease. Currently, these treatments are most frequently applied to triple-negative breast cancer (TNBC), which lacks the receptors targeted by hormone-based therapies. [1]

  • Pembrolizumab: blocks a specific protein on cancer cells that allows them to hide from the immune system. It is used for both high-risk early-stage TNBC, often before and after surgery, and metastatic cases that carry specific tumor markers. [1]

  • Dostarlimab: approved for advanced solid tumors, which can include breast cancer, that have a specific genetic biomarker (mismatch repair deficiency) and have grown during or after other treatments.

How Is Immunotherapy Given, and for How Long?

Receiving immunotherapy is a clinical process that requires regular visits to a healthcare facility. The medication is delivered directly into the bloodstream to ensure optimal distribution throughout the body.

  • Method: intravenous (IV) line injection into the veins. [1]

  • Frequency: typically every three to six weeks.

  • Duration: can last from several months up to two years, depending on the case.

Conceptual illustration of the clinical pathway for receiving immunotherapy treatments for breast cancer – rinnit.com

What Are the Side Effects and Risks of Immunotherapy?

While immunotherapy is designed to target cancer cells, it can sometimes cause the immune system to become overactive or affect healthy tissues. Patients are closely monitored throughout their treatment course to manage these reactions. [1]

Common side effects often include persistent fatigue, skin rashes, diarrhea, and issues with the thyroid gland. More serious but less frequent risks include infusion reactions, characterized by fever, chills, or breathing difficulties, and autoimmune reactions, in which the immune system begins to attack healthy organs.

Illustration of clinical monitoring and supportive care during immunotherapy sessions – rinnit.com

What Is the Outlook After Immunotherapy?

The success of immunotherapy is measured by improved cure rates and extended survival, particularly for patients with triple-negative breast cancer. Ongoing research is evaluating these treatments for other types of the disease, including HER2-positive and ER-positive breast cancers.

Conceptual representation of the transition to wellness and long-term recovery following breast cancer treatment – rinnit.com

Conclusion

Immunotherapy has emerged as a vital tool in the fight against breast cancer, offering new hope for those with high-risk and metastatic conditions. By training the body's own defenses, it provides a powerful supplement to traditional surgical and chemical interventions. As clinical trials continue to expand, the potential for these treatments to help a broader range of patients remains a significant focus of modern oncology.

Next Steps

Patients diagnosed with high-risk or metastatic triple-negative breast cancer should consult with their oncology team to determine whether they are candidates for approved immunotherapy drugs. Discussing the potential for clinical trials can also provide access to emerging treatments that may further improve long-term outcomes.

Frequently Asked Questions (FAQ)

What is immunotherapy for breast cancer?

Immunotherapy for breast cancer is a treatment that boosts your immune system to help it find and kill breast cancer cells.

Who is a candidate for this treatment?

Currently, it is primarily used for high-risk early-stage and metastatic triple-negative breast cancer.

How does active immunotherapy differ from passive immunotherapy?

Active immunotherapy trains the immune system to find specific antigens, while passive immunotherapy enhances existing immune tools.

What is triple-negative breast cancer?

Triple-negative breast cancer is a type of breast cancer that lacks three common receptors, making it a primary target for immunotherapy.

How is the medication administered?

The medication is delivered through an intravenous (IV) line into your veins.

How often will I receive treatments?

Most patients receive a dose every three to six weeks.

How long does the overall treatment last?

The overall treatment can range from a few months up to two years, depending on individual needs.

What are the most common side effects?

Fatigue, skin rashes, diarrhea, and thyroid issues are frequently reported.

What is an infusion reaction?

An infusion reaction is a serious side effect during administration that can cause fever, chills, or breathing trouble.

Can immunotherapy cause autoimmune issues?

Yes, it can sometimes cause the immune system to attack healthy parts of the body.

Does immunotherapy work better than chemotherapy alone?

Studies show that combining certain immunotherapies with chemotherapy can lead to longer survival.

Is immunotherapy used for HER2-positive breast cancer?

Immunotherapy is currently being evaluated in clinical trials for HER2-positive and ER-positive types.

What is the role of pembrolizumab?

Pembrolizumab blocks a protein that helps cancer cells hide from the immune system.

What are biomarkers in this context?

Biomarkers are specific tumor markers that indicate whether a patient's cancer is likely to respond to a certain drug.

What should I do if I experience side effects?

Contact your healthcare team immediately to manage any reactions or symptoms.

Related Reading

Triple-Negative Breast Cancer (TNBC): Symptoms, Causes, Diagnosis and Treatment — What You Need to Know explains the breast cancer type most often treated with immunotherapy.

Immunotherapy Side Effects: Managing Your Cancer Treatment Journey explains immune-related side effects and when to report them.

Immunotherapy for Cancer: How It Works and What to Expect gives an overview of how immunotherapy fights many cancers.

Chemotherapy for Breast Cancer: Types, Timing and Side Effects explains chemotherapy, often given together with breast cancer immunotherapy.

References

  1. Mayo Clinic Staff. Immunotherapy for breast cancer. Mayo Clinic. September 5, 2026. https://www.mayoclinic.org/tests-procedures/immunotherapy-for-breast-cancer/about/pac-20605579

  2. Schmid P, et al. Pembrolizumab for Early Triple-Negative Breast Cancer. New England Journal of Medicine. 2020;382(9):810-821. PMID 32101663. https://doi.org/10.1056/NEJMoa1910549

  3. Cortes J, et al. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. New England Journal of Medicine. 2022;387(3):217-226. PMID 35857659. https://doi.org/10.1056/NEJMoa2202809

  4. Cleveland Clinic. Immunotherapy for Breast Cancer. Cleveland Clinic. Last updated October 19, 2023. https://my.clevelandclinic.org/health/treatments/21939-immunotherapy-treatment-breast-cancer

Medical disclaimer

Medical disclaimer: This content is for informational purposes only and does not constitute medical advice. Always seek the advice of a qualified healthcare professional regarding any medical condition or treatment.

Comments


Spotted an error or a dead link? Tell us

 

Want another health topic explained?

bottom of page